Takeda seals $1.2 billion oncology deal with Innovent Biologics
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
It's an acquisition that aims at forming one of the US's largest oncology trial networks
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
VitiPure serves as essential solubilizers, emulsifiers, and bioavailability enhancers in drug formulations
The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
The technology is intended to support imaging-based training, protocol optimisation and surgical planning
The BlueSeal Horizon 3.0T platform incorporates advanced magnet technology
Subscribe To Our Newsletter & Stay Updated